Home › Funds › Artia Global Partners LP › XENE
Artia Global Partners LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
Artia Global Partners LP reported holding 65,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$3.9M, representing 0.72% of its reported portfolio and ranking #32 among its reported holdings. Artia Global Partners LP has disclosed XENE holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's XENE position evolved
Artia Global Partners LP first disclosed a stake in XENE in Q1 2024 at 40,000 shares (US$1.7M). The position peaked in Q2 2026 at 65,000 shares, worth US$3.9M. Across 10 filings, Artia Global Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 65,000 shares valued at US$3.9M. Notable position changes include a 62% increase in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 40.00K | $1.72M | New |
| Q2 2024 | 40.00K | $1.56M | Hold |
| Q3 2024 | 40.00K | $1.57M | Hold |
| Q4 2024 | 40.00K | $1.57M | Hold |
| Q1 2025 | 40.00K | $1.34M | Hold |
| Q2 2025 | 40.00K | $1.25M | Hold |
| Q3 2025 | 40.00K | $1.61M | Hold |
| Q4 2025 | 40.00K | $1.79M | Hold |
| Q1 2026 | 65.00K | $3.78M | Add |
| Q2 2026 | 65.00K | $3.92M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.78M sh · $348.75M · Q2 2026
- Polar Capital Holdings Plc 4.57M sh · $275.88M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.42M sh · $266.70M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.59M sh · $96.27M · Q2 2026
- Siren, L.L.C. 1.32M sh · $79.59M · Q2 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Caption Management, LLC 728.00K sh · $43.94M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
- Rock Springs Capital Management LP 683.91K sh · $41.28M · Q2 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held XENE?
Artia Global Partners LP has disclosed XENE holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Artia Global Partners LP's current position in XENE?
As of Q2 2026, Artia Global Partners LP holds 65.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $3.92M, representing 0.72% of its reported portfolio and ranking #32.
Has Artia Global Partners LP been buying or selling XENE?
In the latest 13F filing (Q2 2026), Artia Global Partners LP held unchanged its position in XENE. The position peaked in Q2 2026 at 65.00K shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.